Atea Pharmaceuticals, Inc. Income Statement
AVIR|3 years of annual SEC 10-K data (FY2020-FY2022)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
N/A
FY2022
Gross Profit
N/A
FY2022
Operating Income
-$131M
FY2022
Net Income
-$116M
FY2022
Revenue increased 0.0% from FY2020 to FY2021.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | - | $48.6M | $48.6M |
| SG&A Expense | $48.7M | $4.4M | $2.8M |
| R&D Expense | $81.9M | $10.2M | $6.7M |
| Operating Income | -$130.7M | -$14.6M | -$9.5M |
| Income Tax | -$3.6M | $17.4M | - |
| Net Income | -$115.9M | -$14.0M | -$9.1M |
| EPS (Basic) | -$0.51 | -$1.39 | - |
| EPS (Diluted) | -$0.51 | -$1.39 | -$0.90 |
| Shares Outstanding | 83.1M | 82.4M | 10.1M |
| Operating Margin | - | -30.0% | -19.5% |
| Profit Margin | - | -28.9% | -18.6% |